Reference is made to the stock exchange announcements by
The Subsequent Offering consists of an offering of up to 1,000,000 new shares in the Company (the "
In addition, the following types of investors shall have a secondary right to subscribe for the Offer Shares; (i) ABTEC shareholders and investors that participated in the Private Placement, (ii), and (iii) other subscribers without Subscription Rights (as defined below), subject to a minimum allocation of at least
The subscription period in the Subsequent Offering commences on
In the Subsequent Offering, Eligible Shareholders, will be granted non-transferable subscription rights (the "Subscription Rights") that, subject to applicable law, provide preferential rights to subscribe for and be allocated
The Eligible Shareholders will be granted a certain number of Subscription Rights for each existing share registered as held by such Eligible Shareholder as of the Record Date, rounded down to the nearest whole number of Subscription Rights. Secondary Subscribers will not be granted Subscription Rights. Each whole Subscription Right will provide a preferential right to subscribe for, and be allocated, one Offer Share at the Subscription Price. Over-subscription will be permitted. Other than subscriptions from Secondary Subscribers, subscription without Subscription Rights will not be permitted.
The Subscription Rights must be used to subscribe for
Completion of the Subsequent Offering is subject to, inter alia, approval from the Company's Board of Directors. The Offer Shares allocated in the Subsequent Offering will be resolved issued by the Board of Directors pursuant to an authorization to increase the share capital.
An invitation letter (the "Invitation Letter") will be prepared in connection with the Subsequent Offering, which sets out the terms and conditions for the Subsequent Offering and includes a description of certain risk factors pertaining to the Company, its shares, and the Subsequent Offering.
The Invitation Letter and the specific number of subscription rights for each Eligible Shareholder will be published prior to the start of the subscription period, and will also be made available at websites of Norne Securities AS, www.norne.no/ABTEC.
Norne Securities AS is acting as Settlement Agent for the Subsequent Offering.
* * *
For further information, please contact Håvard Lindstrøm, CEO, telephone +47 941 32 288.
This information is subject of the disclosure requirements pursuant to section of 5-12 of the Norwegian Securities Trading Act.
Disclosure regulation
This information is subject of the disclosure requirements pursuant to section of 5-12 of the Norwegian Securities Trading Act.
Contacts
- Håvard Lindstrøm, 004794132288, hl@aquabiotech.no
About Aqua Bio Technology ASA
biotechnology for use in skin care products. ABT's cosmetics ingredients are
highly effective and they provide the cosmetics industry with natural
alternatives to traditional ingredients. ABT is also marketing and distributing
natural skin care products developed by partners towards consumers and
professional users.
Attachments
- Download announcement as PDF.pdf
© NTB Norway, source